Skip to main content
OpenTrials
Completed

NCT Number: NCT02287298

Triple Combination Therapy of Choroidal Neovascularization in AMD, a Cost Effect and Efficient Therapeutic Treatment

We propose to undertake a retrospective review of approximately 200 patients with a diagnosis of exudative macular degeneration treated with triple combination therapy (Bevacizumab, Dexamethasone and Photo-dynamic therapy) during the years of 2006 to 2010 at The Retina Center and compare those results with an additional group of approximately 200 patients also treated with triple combination therapy and 20 mg of daily oral zeaxanthin.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Exudative Macular Degeneration Eye Diseases Macular Degeneration Retinal Degeneration Retinal Diseases Wet Macular Degeneration

Age range

50 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

The Retina Center

St Louis, Missouri, 63141, United States

About this study

Study parameters will include best corrected visual acuity, number of combination treatments, reduction of central foveal thickness by OCT measurement and development of exudative macular degeneration in the fellow eye. Follow up will include all patients with a minimum of two years. Retrospective review of patient charts in the office of The Retina Center.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • MUST HAVE AGE RELATED MACULAR DEGENERATION

Exclusion criteria

-

Treatment and study plan

TRIPLE COMBINATION THERAPY

Procedure

TREATMENT WITH BEVACIZUMAB, DEXAMETHASONE AND PHOTODYNAMIC THERAPY

Primary outcomes

  1. BEST CORRECTED VISUAL ACUITY

    Time frame: REVIEW OF EXAMINATION SHEETS

Secondary outcomes

  1. NUMBER OF COMBINATION TREATMENTS

    Time frame: REVIEW OF CHART

  2. REDUCTION OF CENTRAL FOVEAL THICKNESS BY OCT MEASUREMENT

    Time frame: REVIEW OF CHART

  3. DEVELOPMENT OF EXUDATIVE MACULAR DEGENERATION IN THE FELLOW EYE

    Time frame: REVIEW OF CHART

Sponsors and collaborators

Lead sponsor

The Retina Center of St. Louis County, PC

Other

Registry information

Official study title

Triple Combination Therapy of Choroidal Neovascularization in Exudative Age-related Macular Degeneration - a Cost Effect and Efficient Therapeutic Treatment

Important dates

Study start
2014
Primary completion
2015
Study completion
2015
First posted
Nov 10, 2014
Registry last updated
Apr 6, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.